NewAmsterdam Pharma Company NV (OQ:NAMS)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | Gooimeer 2-35 NAARDEN 1411 DC |
| Tel: | N/A |
| Website: | https://ir.newamsterdampharma.com |
| IR: | See website |
| Key People | ||
| Michael Harvey Davidson Chief Executive Officer, Executive Director | Michael Harvey Davidson Chief Executive Officer, Executive Director | Louise Kooij Interim Chief Financial Officer |
| Louise Kooij Interim Chief Financial Officer | Douglas Kling Chief Operating Officer | Douglas Kling Chief Operating Officer |
| John Kastelein Chief Scientific Officer, Non-Executive Director | John Kastelein Chief Scientific Officer, Non-Executive Director | Juliette Audet Chief Business Officer |
| Juliette Audet Chief Business Officer | Marc Ditmarsch Chief Development Officer | Marc Ditmarsch Chief Development Officer |
| Business Overview |
| NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer's disease. The Company strives to offer its products around the world. |
| Financial Overview |
| For the six months ended 30 June 2023, NewAmsterdam Pharma Company NV revenues decreased 90% to EUR9.6M. Net loss totaled EUR75.1M vs. income of EUR54.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects SGA increase of 91% to EUR8.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR0.67 to -EUR0.91. |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
